ThaiPR.NET https://www.thaipr.net/location/florence-italy-and-new-york Press Release Distribution Center of Thailand Fri, 24 Apr 2026 17:45:02 +0700 hourly 1 https://wordpress.org/?v=6.1.1 <![CDATA[Menarini Group and Insilico Medicine Enter Global Exclusive License Agreement for Novel KAT6 Inhibitor for Potential Breast Cancer Treatment and Other Oncology Indications]]> https://www.thaipr.net/en/health_en/3429424 Fri, 05 Jan 2024 17:23:47 +0700 health_en https://www.thaipr.net/en/health_en/3429424 The Menarini Group (“Menarini”), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. (“Stemline”), a wholly-owned subsidiary of the Menarini Group focused on bringing transformational oncology treatments to cancer patients, along with clinical stage generative artificial intelligence (AI)-driven biotechnology company Insilico Medicine (“Insilico”), today announced that they have entered into an exclusive licensing agreement […]

The post Menarini Group and Insilico Medicine Enter Global Exclusive License Agreement for Novel KAT6 Inhibitor for Potential Breast Cancer Treatment and Other Oncology Indications appeared first on ThaiPR.NET.

]]> <![CDATA[Menarini Group Presented Initial Safety and Efficacy Data from Phase 1b/2 ELEVATE and ELECTRA Combination Studies of ORSERDU® (Elacestrant) in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2023 San Antonio Breast Cancer Symposium]]> https://www.thaipr.net/en/health_en/3421894 Wed, 13 Dec 2023 08:25:17 +0700 health_en https://www.thaipr.net/en/health_en/3421894 The Menarini Group (“Menarini”), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. (“Stemline”), a wholly-owned subsidiary of the Menarini Group, focused on bringing transformational oncology treatments to cancer patients, presented results from phase 1b/2 ELEVATE and ELECTRA clinical studies evaluating ORSERDU® (elacestrant) in combination with other treatments. Both the ELEVATE and ELECTRA […]

The post Menarini Group Presented Initial Safety and Efficacy Data from Phase 1b/2 ELEVATE and ELECTRA Combination Studies of ORSERDU® (Elacestrant) in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2023 San Antonio Breast Cancer Symposium appeared first on ThaiPR.NET.

]]> <![CDATA[Menarini Group Presents New Progression-Free Survival Data from EMERALD Clinical Study of ORSERDU® (Elacestrant) in Clinically Relevant Subgroups of Patients with ER+, HER2- Metastatic Breast Cancer (mBC) with ESR1 Mutations at SABCS 2023]]> https://www.thaipr.net/en/health_en/3421813 Tue, 12 Dec 2023 16:54:23 +0700 health_en https://www.thaipr.net/en/health_en/3421813 The Menarini Group (“Menarini”), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. (“Stemline”), a wholly-owned subsidiary of the Menarini Group, focused on bringing transformational oncology treatments to cancer patients, today presented results from a new post hoc analysis of the pivotal EMERALD clinical study that demonstrated a clinically meaningful improvement in progression-free […]

The post Menarini Group Presents New Progression-Free Survival Data from EMERALD Clinical Study of ORSERDU® (Elacestrant) in Clinically Relevant Subgroups of Patients with ER+, HER2- Metastatic Breast Cancer (mBC) with ESR1 Mutations at SABCS 2023 appeared first on ThaiPR.NET.

]]> <![CDATA[Menarini Group Announces New Data on ORSERDU® (elacestrant) at the 2023 San Antonio Breast Cancer Symposium and on ELZONRIS® (tagraxofusp-erzs) at the 65th American Society of Hematology Annual Meeting and Exposition]]> https://www.thaipr.net/en/health_en/3413765 Thu, 23 Nov 2023 08:00:00 +0700 health_en https://www.thaipr.net/en/health_en/3413765 – Data spans eleven presentations across both solid tumors and hematologic malignancies, providing added understanding of the potential benefit these therapies bring to patients – ORSERDU data reinforce its key role in the treatment of ER+, HER2- advanced or metastatic breast cancer (mBC) tumors that harbor ESR1 mutations, while showing initial data from combination trials – ELZONRIS presentation […]

The post Menarini Group Announces New Data on ORSERDU® (elacestrant) at the 2023 San Antonio Breast Cancer Symposium and on ELZONRIS® (tagraxofusp-erzs) at the 65th American Society of Hematology Annual Meeting and Exposition appeared first on ThaiPR.NET.

]]> <![CDATA[European Commission Approves Menarini Group’s ORSERDU® (Elacestrant) for the Treatment of Patients with ER+, HER2- Locally Advanced or Metastatic Breast Cancer with an Activating ESR1 Mutation]]> https://www.thaipr.net/en/health_en/3386945 Fri, 22 Sep 2023 08:00:00 +0700 health_en https://www.thaipr.net/en/health_en/3386945 The Menarini Group (“Menarini”), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics Inc. (“Stemline”), a wholly-owned subsidiary of the Menarini Group, announced today that the European Commission has approved ORSERDU® (elacestrant) as a monotherapy for the treatment of postmenopausal women, and men, with estrogen receptor (ER)–positive, HER2-negative, locally advanced or metastatic breast cancer […]

The post European Commission Approves Menarini Group’s ORSERDU® (Elacestrant) for the Treatment of Patients with ER+, HER2- Locally Advanced or Metastatic Breast Cancer with an Activating ESR1 Mutation appeared first on ThaiPR.NET.

]]> <![CDATA[The Menarini Group Announces ELZONRIS® (Tagraxofusp) Designated as an Orphan Drug for BPDCN by Japanese Ministry of Health, Labor and Welfare]]> https://www.thaipr.net/en/health_en/3377234 Fri, 01 Sep 2023 08:00:00 +0700 health_en https://www.thaipr.net/en/health_en/3377234 The Menarini Group (“Menarini”), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. (“Stemline”), a wholly-owned subsidiary of the Menarini Group, today announced that Nippon Shinyaku Co., Ltd. (Nippon Shinyaku), Stemline’s development partner in Japan, received Orphan Drug Designation for tagraxofusp, from the Japanese Ministry of Health, Labor and Welfare (MHLW) for the […]

The post The Menarini Group Announces ELZONRIS® (Tagraxofusp) Designated as an Orphan Drug for BPDCN by Japanese Ministry of Health, Labor and Welfare appeared first on ThaiPR.NET.

]]> <![CDATA[Menarini Group Receives Positive CHMP Opinion Recommending EC Approval of ORSERDU® (Elacestrant) for the Treatment of Patients with ER+, HER2- Locally Advanced or Metastatic Breast Cancer with an Activating ESR1 Mutation]]> https://www.thaipr.net/en/health_en/3362171 Mon, 24 Jul 2023 15:10:55 +0700 health_en https://www.thaipr.net/en/health_en/3362171 The Menarini Group (“Menarini”), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics Inc. (“Stemline”), a wholly-owned subsidiary of the Menarini Group, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion on the approval of ORSERDU® (elacestrant) monotherapy, indicated for […]

The post Menarini Group Receives Positive CHMP Opinion Recommending EC Approval of ORSERDU® (Elacestrant) for the Treatment of Patients with ER+, HER2- Locally Advanced or Metastatic Breast Cancer with an Activating ESR1 Mutation appeared first on ThaiPR.NET.

]]> <![CDATA[Menarini Group Shares New Analysis from EMERALD Clinical Study of ORSERDU® (Elacestrant) in Metastatic Breast Cancer at ASCO 2023]]> https://www.thaipr.net/en/health_en/3341717 Mon, 29 May 2023 12:58:50 +0700 health_en https://www.thaipr.net/en/health_en/3341717 The Menarini Group (“Menarini”), a leading Italian pharmaceutical and diagnostics company, and Stemline Therapeutics (“Stemline”), a wholly-owned subsidiary of the Menarini Group, today announced results from a new analysis of the pivotal EMERALD clinical study that suggest that oral single-agent elacestrant may be effective in ER+, HER2- advanced or metastatic breast cancer patients with Non-Detected ESR1-mut […]

The post Menarini Group Shares New Analysis from EMERALD Clinical Study of ORSERDU® (Elacestrant) in Metastatic Breast Cancer at ASCO 2023 appeared first on ThaiPR.NET.

]]> <![CDATA[Menarini Group Announces New Data on Elacestrant at 2023 ESMO Breast Cancer Congress and 2023 ASCO Annual Meeting]]> https://www.thaipr.net/en/health_en/3335101 Thu, 11 May 2023 08:54:08 +0700 health_en https://www.thaipr.net/en/health_en/3335101 The Menarini Group (“Menarini”), a leading Italian pharmaceutical and diagnostics company, and Stemline Therapeutics (“Stemline”), a wholly-owned subsidiary of the Menarini Group, announced today that they will present new data related to elacestrant in upcoming congresses. Elacestrant has been approved by the FDA for treatment of postmenopausal women or adult men with estrogen receptor (ER)-positive, […]

The post Menarini Group Announces New Data on Elacestrant at 2023 ESMO Breast Cancer Congress and 2023 ASCO Annual Meeting appeared first on ThaiPR.NET.

]]> <![CDATA[Stemline Therapeutics, a subsidiary of Menarini Group, Receives U.S. FDA Approval for ORSERDUTM (elacestrant) as the First and Only Treatment Specifically Indicated for Patients with ESR1 Mutations in ER+, HER2- Advanced or Metastatic Breast Cancer]]> https://www.thaipr.net/en/health_en/3296882 Wed, 01 Feb 2023 08:00:00 +0700 health_en https://www.thaipr.net/en/health_en/3296882 The Menarini Group (“Menarini”), a leading Italian pharmaceutical and diagnostics company, announced today that the U.S. Food and Drug Administration (FDA) has approved ORSERDU for the treatment of postmenopausal women or adult men, with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy. Stemline Therapeutics (“Stemline”), a […]

The post Stemline Therapeutics, a subsidiary of Menarini Group, Receives U.S. FDA Approval for ORSERDUTM (elacestrant) as the First and Only Treatment Specifically Indicated for Patients with ESR1 Mutations in ER+, HER2- Advanced or Metastatic Breast Cancer appeared first on ThaiPR.NET.

]]> <![CDATA[Menarini Group’s Elacestrant Marketing Authorization Application Accepted for Review by the European Medicines Agency (EMA) for the Treatment of ER+/HER2- Advanced or Metastatic Breast Cancer]]> https://www.thaipr.net/en/health_en/3227729 Mon, 22 Aug 2022 08:00:00 +0700 health_en https://www.thaipr.net/en/health_en/3227729 Elacestrant, if approved, would be the first oral selective estrogen receptor degrader (SERD) to be available for patients suffering from second-line (2L) and third-line (3L) ER+/HER2- advanced or metastatic breast cancer in the European Union Submission supported by results from the pivotal Phase 3 EMERALD study showing a statistically significant difference in the efficacy in favor […]

The post Menarini Group’s Elacestrant Marketing Authorization Application Accepted for Review by the European Medicines Agency (EMA) for the Treatment of ER+/HER2- Advanced or Metastatic Breast Cancer appeared first on ThaiPR.NET.

]]>